JP2014510152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510152A5 JP2014510152A5 JP2014504014A JP2014504014A JP2014510152A5 JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5 JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- viscosity
- acetate
- reduced
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 56
- 239000000203 mixture Substances 0.000 claims 56
- 238000000034 method Methods 0.000 claims 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 239000004475 Arginine Substances 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 229930182817 methionine Natural products 0.000 claims 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229940100602 interleukin-5 Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 159000000021 acetate salts Chemical class 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473123P | 2011-04-07 | 2011-04-07 | |
| US61/473,123 | 2011-04-07 | ||
| PCT/US2012/032464 WO2012141978A2 (en) | 2011-04-07 | 2012-04-06 | Formulations with reduced viscosity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510152A JP2014510152A (ja) | 2014-04-24 |
| JP2014510152A5 true JP2014510152A5 (enExample) | 2015-05-21 |
Family
ID=47009919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504014A Pending JP2014510152A (ja) | 2011-04-07 | 2012-04-06 | 粘度が低減された処方物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140044727A1 (enExample) |
| EP (1) | EP2694708A4 (enExample) |
| JP (1) | JP2014510152A (enExample) |
| KR (1) | KR20140066124A (enExample) |
| CN (1) | CN103582724A (enExample) |
| AU (1) | AU2012243126A1 (enExample) |
| BR (1) | BR112013025845A2 (enExample) |
| CA (1) | CA2832560A1 (enExample) |
| EA (1) | EA201391489A1 (enExample) |
| IL (1) | IL228626A0 (enExample) |
| SG (1) | SG193964A1 (enExample) |
| WO (1) | WO2012141978A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3295957T1 (sl) * | 2010-01-15 | 2020-02-28 | Kirin-Amgen, Inc. | Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice |
| WO2012138958A1 (en) * | 2011-04-07 | 2012-10-11 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| MX2014014717A (es) * | 2012-06-21 | 2015-03-06 | Ucb Pharma Sa | Formulacion farmaceutica. |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN116327922A (zh) | 2015-08-24 | 2023-06-27 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 生物医药组合物 |
| CN105733250B (zh) * | 2016-05-04 | 2017-12-26 | 山东省药学科学院 | 一种交联聚谷氨酸悬浮液及其制备方法与应用 |
| CN110167531B (zh) * | 2017-01-11 | 2025-06-03 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| HRP20240167T1 (hr) | 2017-04-28 | 2024-04-26 | Amgen Inc. | Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe |
| RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| WO2018226339A1 (en) * | 2017-06-06 | 2018-12-13 | Glaxosmithkline Llc | Biopharmaceutical compositions and methods for pediatric patients |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| CN113056482A (zh) | 2018-10-18 | 2021-06-29 | 默沙东公司 | 抗rsv抗体的制剂及其使用方法 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| US12599669B2 (en) * | 2019-04-23 | 2026-04-14 | Amgen Inc. | Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4340062B2 (ja) * | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
| US20050164929A1 (en) * | 2000-11-06 | 2005-07-28 | Lupine Logic, Inc. | Methods of preventing and treating inflammatory bowel disease |
| MXPA05004528A (es) * | 2002-11-01 | 2005-07-26 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| PL1942939T5 (pl) * | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP2173163A4 (en) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | ANTIBODY FORMULATIONS |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AU2008304111B2 (en) * | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| CN102958538A (zh) * | 2010-05-03 | 2013-03-06 | 弗·哈夫曼-拉罗切有限公司 | 用于降低含有蛋白质的制剂的粘度的组合物和方法 |
-
2012
- 2012-04-06 SG SG2013072434A patent/SG193964A1/en unknown
- 2012-04-06 WO PCT/US2012/032464 patent/WO2012141978A2/en not_active Ceased
- 2012-04-06 US US14/110,252 patent/US20140044727A1/en not_active Abandoned
- 2012-04-06 CA CA2832560A patent/CA2832560A1/en not_active Abandoned
- 2012-04-06 EP EP12771966.4A patent/EP2694708A4/en not_active Withdrawn
- 2012-04-06 AU AU2012243126A patent/AU2012243126A1/en not_active Abandoned
- 2012-04-06 JP JP2014504014A patent/JP2014510152A/ja active Pending
- 2012-04-06 BR BR112013025845A patent/BR112013025845A2/pt not_active IP Right Cessation
- 2012-04-06 CN CN201280025770.0A patent/CN103582724A/zh active Pending
- 2012-04-06 EA EA201391489A patent/EA201391489A1/ru unknown
- 2012-04-06 KR KR1020137029164A patent/KR20140066124A/ko not_active Withdrawn
-
2013
- 2013-09-29 IL IL228626A patent/IL228626A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516924A5 (enExample) | ||
| RU2020123963A (ru) | Стабилизированные препараты, содержащие антитела против ngf | |
| JP2020537520A5 (enExample) | ||
| JP2019503349A5 (enExample) | ||
| JP2013543505A5 (enExample) | ||
| IL283424B2 (en) | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) | |
| RU2016129624A (ru) | Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| RU2013155695A (ru) | Препараты антител против с-мет | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2017515909A5 (enExample) | ||
| MX363226B (es) | Formulaciones de anticuerpos. | |
| JP2013535190A5 (enExample) | ||
| RU2015137685A (ru) | Композиции антитела в низкой концентрации | |
| JP2014522843A5 (enExample) | ||
| EA200970880A1 (ru) | Стабильные композиции на основе антител | |
| RU2015123476A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP2014502955A5 (enExample) | ||
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| FI3355919T3 (fi) | Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä | |
| JP2016539096A5 (enExample) |